Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
Inclusion Criteria:
- Advanced epithelial, tubal, or primary peritoneal cancer
- Cancer cells in paracentesis, thoracentesis, or laparoscopic surgery
- Less probability of complete cytoreduction
- Age: 20-80 years
- GOG performance status: 0-3
- Adequate organ function Bone marrow: ANC ≥ 1,500mm3, Platelet ≥ 100,000/mm3, Hb ≥
10.0 g/dl Kidney: Creatinine ≤ 1.25 × UNL Liver: AST, ALT ≤ × 2.5 UNL (in case of
liver metastasis, AST, ALT ≤ × 5 UNL), alkaline phosphatase ≤ 5 x UNL, bilirubin ≤
1.5 mg/ mm3
Exclusion Criteria:
- Previous chemotherapy or pelvic radiation therapy
- Final diagnosis is other malignancies
- Coincidental Other malignancies within 5 years except carcinoma in situ of uterine
cervix
- History of severe allergy
- Pregnancy, lactating woman
- Uncontrolled medial disease
- Bowel obstruction requiring immediate surgery
- Etc.